Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

 – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year –

– Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year –

– Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter –

– Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million –

– Ended Q2’25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million –

– Board of Directors Authorized $150 Million Share Repurchase Program –

– Conference Call Scheduled for Today at 8:00 a.m. ET –

The Company will host a conference call and live audio webcast on Thursday, August 7, 2025, at 8:00 a.m. ET. To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Second Quarter 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

https://finance.yahoo.com/news/collegium-reports-second-quarter-2025-113000873.html